IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Newer approaches on rDNA technology in vaccine development

[1]Keerthana g , [2]Dr M Vijay bhargavi ma'am

[1]Student, [2]assistant professor, HOD of pharmaceutical chemistry.
[1.2] Rbvrr women's college of pharmacy, secunderabad, telangana.

ABSTRACT : AN OVERVIEW OF MORE RECENT METHODS FOR DEVELOPING VACCINES USING RECOMBINANT DNA (RDNA) TECHNOLOGY IS GIVEN IN THIS ARTICLE. THROUGH THE USE OF GENETIC ENGINEERING, RECOMBINANT VACCINES GENERATE ANTIGENS OR PROTEINS THAT ELICIT AN IMMUNE RESPONSE. SELECTING ANTIGENS, COPYING DNA, TRANSFERRING GENETIC MATERIAL INTO HOST CELLS, AND INDUCING ANTIGEN EXPRESSION ARE ALL STEPS IN THE PROCESS. BENEFITS OF RECOMBINANT VACCINES INCLUDE INCREASED PROTECTION POTENTIAL, SIMPLICITY OF MANUFACTURE, SAFETY, AND SPECIFICITY.

IT EXPLORES RECOMBINANT DNA TECHNOLOGY AND EXPLAINS HOW PROCESSES INCLUDING DNA SEPARATION, ALTERATIONS USING PCR OR RESTRICTION ENZYMES, AND INSERTION INTO A VECTOR MAY CHANGE AN ORGANISM'S GENETIC COMPOSITION. THIS TECHNIQUE IS WIDELY USED IN THE PHARMACEUTICAL, AGRICULTURAL, AND INDUSTRIAL SECTORS. IT ALSO MAKES IT EASIER TO PRODUCE GENETICALLY MODIFIED CROPS AND THERAPEUTIC PROTEINS.

A VARIETY OF RDNA VACCINES ARE INVESTIGATED, SUCH AS VACCINES BASED ON SUBUNITS, RECOMBINANT PROTEINS, AND VIRUS-LIKE PARTICLES (VLPS). SUBUNIT VACCINES ARE MADE OF COMPONENTS THAT HAVE BEEN PURIFIED; THEY HAVE BEEN SHOWN TO BE SAFE BUT MAY PRESENT IMMUNOGENICITY ISSUES. THE HEPATITIS B AND HUMAN HPV VACCINES ARE TWO EXAMPLES OF RECOMBINANT PROTEIN VACCINES THAT SHOW THEIR EFFECTIVENESS BY EXPRESSING CERTAIN ANTIGENS. MOLECULARLY IMITATING VIRUSES WITHOUT INFECTIOUS CHARACTERISTICS, OR VLP VACCINES, PROVIDE EFFECTIVE AND SECURE IMMUNIZATION ALTERNATIVES.

FINALLY, WE MAY SUMMARIZE THE ADVANTAGES OF VLP VACCINATIONS, STRESSING THEIR POTENTIAL TO PROVIDE STRONG IMMUNITY, SAFETY, AND FLEXIBILITY IN THE FACE OF CHANGING VIRUS VARIATIONS. IN GENERAL, RDNA TECHNOLOGY HAS REVOLUTIONIZED THE DEVELOPMENT OF VACCINES BY GIVING SCIENTISTS THE MEANS TO CREATE SAFER AND MORE POTENT VACCINATIONS AGAINST A RANGE OF INFECTIOUS ILLNESSES. THE REFERENCES PROVIDE RELIABLE SOURCES THAT BOLSTER THE IDEAS THAT HAVE BEEN EXPLORED.

1Introduction

Recombinant vaccines are a form of vaccination that uses recombinant DNA technology to manufacture certain antigens or proteins that trigger an immune response in the recipient. They are sometimes referred to as genetic vaccines or DNA vaccines. These vaccines work by introducing genetic material that encodes the target antigen into the body, which causes the recipient's cells to start producing the target antigen.

I. RECOMBINANT VACCINES FUNCTION AS FOLLOWS:

1. Selecting the antigen(s) that will trigger an immune response against the target disease is the first stage in creating a recombinant vaccine. These antigens may take the form of surface proteins, poisons, or other substances that the immune system may identify and react to.
2. DNA cloning is the process of separating the gene encoding the chosen antigen from the genetic material of the disease and putting it into an appropriate DNA carrier, frequently a plasmid. The components required for gene expression are provided by the plasmid, which also acts as a carrier for the gene.
3. Introduction to Host Cells: The recipient's cells are given the recombinant DNA, which contains the gene encoding the antigen. Several techniques, including direct injection, electroporation, and the use of viral vectors, can be used to accomplish this. The machinery of the cells absorbs the DNA when it enters the cells.
4. Antigen Expression: After entering the host cells, the recombinant DNA is translated into messenger RNA (mRNA), which the cell's protein synthesis machinery subsequently converts into protein. The DNA inserted causes the cells to start producing the antigen.
5. Immune Reaction: The immune system identifies the antigen generated by the host cells as alien. As a result, the immune system is triggered, producing antibodies and triggering the activation of immune cells including T cells and B cells. The body can identify the specific infection and create a defense against it thanks to the immunological response that is produced.

Recombinant vaccines provide a number of benefits:

1. **Recombinant vaccines:** lack of live pathogens lowers the danger that they will infect those who have received them with illness.
2. **Specificity:** The chosen antigen may be carefully tailored, enabling specialized immune responses to certain disease components.
3. **EASE:** Recombinant vaccines may be generated easily and in huge numbers utilizing tried-and-true laboratory methods.
4. **Broader Protection Possibility:** Recombinant vaccines have the potential to stimulate both cellular and humoral immune responses, providing greater pathogen protection.

Recombinant vaccines have been successfully created and used to prevent illnesses such as hepatitis B, COVID-19, and the human papillomavirus (HPV). The possibility of creating efficient vaccinations against different infectious illnesses is always expanding because of ongoing research and improvements in recombinant DNA technology.

2 WHAT IS RECOMBINANT DNA TECHNOLOGY?

Recombinant DNA technology, commonly referred to as genetic engineering or gene splicing, is a group of procedures used to modify and change an organism's genetic makeup. Developing novel genetic combinations that are not present in nature, entails mixing DNA molecules from several sources, usually from different species.

The isolation and extraction of DNA from the source species is the first step in the recombinant DNA technology process. Any creature, whether bacteria, plants, animals, or people, can provide this DNA. Once the DNA has been collected, it can be altered in a number of ways.

Utilizing restriction enzymes, which are proteins that can cut DNA at specified sequences, is one typical method. The DNA is divided into pieces by these enzymes. A different approach is the polymerase chain reaction (PCR), which amplifies particular DNA sequences to produce more DNA.

The target DNA pieces are then combined with a vector, typically a tiny, self-replicating DNA molecule. For the DNA fragments to be reproduced and expressed, the vector transports them into a host organism, such as bacteria or yeast.

DNA ligase, an enzyme that can "glue" DNA fragments with complementary ends, is commonly used to combine the DNA fragments and the vector. DNA sequences from the donor organism and the vector are both present in the recombinant DNA molecule that is produced.

The recombinant DNA molecule can then be injected or transformed into the host cells, transfected, or microinjected. When the recombinant DNA is within the host cells, it may be duplicated alongside the DNA of the host cell and expressed to make proteins or other desired products.

The use of recombinant DNA technology is widespread in many industries, including industry, agriculture, and medicine. Through the production of recombinant proteins in bacteria or other host cells, therapeutic proteins like insulin and growth hormones have been produced. Additionally, it has been used to create crops that have been genetically engineered to have better features, such as insect resistance or higher nutritional value.

Overall, recombinant DNA technology has transformed the field of biotechnology by enabling researchers to control and alter genetic material to achieve specific goals. This has sped up research in many fields and led to practical applications.

2.1 DIFFERENT TYPES OF rDNA VACCINES:

2.1.1 SUB-UNIT VACCINES: A subunit vaccination will only contain certain components derived from disease-causing bacteria, parasites, or viruses, as opposed to a whole-pathogen vaccine strategy. Antigens are highly purified proteins or synthetic peptides that are used in these components, which are far safer than whole-pathogen vaccination methods.

Despite these benefits, a subunit vaccine's potential for immunogenicity is diminished since the antigens it contains are relatively tiny and lack the pathogen-associated molecular patterns (PAMPs) that the host immune system needs to recognize.

The possibility for antigen denaturation, which can lead to proteins binding to various antibodies rather than the particular antigens that target the disease, is another flaw of subunit vaccinations.

In contrast to a live attenuated or inactivated vaccination, a "subunit" vaccine simply includes antigenic components, such as proteins, polysaccharides, or peptides. The vaccine is safer and more stable than vaccinations made from complete pathogens since it doesn't include any "live" or infectious components of the pathogen. Being a proven technique and appropriate for those with impaired immune systems are further benefits. Being more difficult to make than certain vaccines, the potential need for adjuvants and booster doses, and the time needed to determine which antigenic combinations could work best are all drawbacks.

To protect patients from Hepatitis B, the first recombinant subunit vaccination was created in the middle of the 1980s. Engerix-B (hepatitis B), Gardasil 9 (human papillomavirus), Flublok (influenza), Shingrix (herpes zoster), and Nuvaxovid (coronavirus illness 2019) are more recombinant subunit vaccines that have received licenses.

Injection-safe recombinant subunit vaccinations are generally accepted. The likelihood of side effects varies based on the particular vaccination being used. Anaphylaxis and possibly deadly allergic response are major adverse effects, whereas injection site discomfort, fever, and exhaustion are minor side effects. The contraindications are also vaccine-specific; generally speaking, they are not advised for those who have previously had hypersensitivity to any vaccination component. Before obtaining any immunization, you should see a medical expert.

2.1.1.1advantages :

1) cannot become virulent again, i.e., they cannot spread the disease they are intended to treat.
2) safe for patients with reduced immunity.
3) able to endure variations in environmental factors such as humidity, light exposure, and temperature.

2.1.1.2 disadvantages:

1) a lower level of immunogenicity than attenuated vaccinations.
   a) Adjuvants are necessary to increase immunogenicity.
   b) For long-lasting immunity, it sometimes takes many doses (also known as "booster" doses).
2) It may be challenging to identify the precise antigen(s) that will trigger the required immunological response.
3) Because of the difficulty in controlling conjugation chemistry, which results in noncontinuous variation.

2.1.2 VACCINES MADE FROM RECOMBINANT PROTEIN:

Today, the majority of vaccines being researched are based on highly purified recombinant proteins or pathogen components. The hepatitis B vaccine is a typical example of a recombinant protein vaccine that is now being used in people. Globally, hepatitis B virus (HBV) infection is a chronic liver disease. Due in part to the expression of a particular receptor on the surface of infected cells, HBV has a notable tropism for human liver cells. The hepatitis B surface antigen (HBsAg) is expressed in yeast cells to create the current vaccinations. The HBV vaccination is very effective because the HBsAg assembles into virus-like particles (VLPs), which are highly immunogenic. The antigen may be secreted by the yeast expression system into the culture supernatant, which might aid in the purifying process. Moreover, yeast cells provide a portion of the eukaryotic cellular machinery that modifies proteins post-translationally by converting them to glycosylated forms. Due to price reductions brought about by competition and the transfer of production technologies to other producers, the HBV vaccination is now accessible to the majority of poor nations.

The human papillomavirus (HPV) vaccine is a more modern example of a recombinant vaccination. One of the most prevalent STDs in the world, HPV is linked to a wide range of mucocutaneous conditions in people, such as genital warts and malignancies of the cervical, vulva, and vaginal regions. There are now two HPV vaccines in use, and they were both created using vector lambda polymorphisms (VLPs) taken from the HPV-6, -11, -16, and/or -18 subtypes. The L1 recombinant proteins of each subtype, which are made in yeast or an insect-cell system, are used in these vaccinations. The primary capsid protein, L1, is expressed in vitro and contributes to the assembly of VLPs.

Aluminum salt was used as an adjuvant in the successful use of recombinant proteins as vaccines, including hepatitis B and, more recently, HPV. As a result, the study of novel adjuvants is a crucial area of vaccination research. Understanding the molecular complexity of novel adjuvants and the processes by which they function to stimulate or trigger the immune response are the biggest challenges to their development. For instance, the mechanism of action of aluminum salts, the adjuvants most often employed in vaccinations for humans and animals worldwide, is still unclear. However, according to a recent study by Richard Flavell's group (15), they would trigger the Nalp3 inflammasome, an intracellular innate immune response mechanism. Exploring the natural adjuvant qualities of living vectors, such as bacteria and viruses, has been one alternate route for antigen presentation. In addition to other considerations, formulation, and safety are crucial factors to take into account.

2.1.3 VACCINES MADE FROM VIRUS-LIKE PARTICLES (VLP):

The acronym for virus-like particles is VLP. Molecular mimics of viruses that lack infectious properties are called virus-like particles. They are a highly efficient method of producing vaccinations against a variety of illnesses, including malaria, hepatitis B, human papillomavirus (HPV), and more.

Since a virus-like particle lacks viral genetic material, it cannot spread disease. A VLP injected into the body will elicit an immune response since they resemble actual viral molecules a great deal, but the recipient will not show any signs of the virus they are being vaccinated against.

PeopLe become resistant to that specific virus once their bodies have mounted an immunological reaction to the VLP. This allows the body to identify the virus and ward off infection in the future.

One or more structural proteins that may be stacked in layers make up a VLP. Additionally, they may have an outer lipid envelope, the outermost coat that envelops a variety of viruses. The genetic material within the virus particle is shielded by this outer coating. Certain viruses can conceal their presence from the immune system by hiding material from the infected individual inside envelopes.

Mammalian, yeast, bacterial, or insect cells can all be used to make a VLP vaccine. The choice of cell type is determined by the expense of producing a vaccine in this manner and by whether post-translational modifications (PTMs) of the VLP are required to elicit the highest immune response.

According to the results of one study, out of 174 VLPs, 28% were made using bacterial systems, 20% utilized yeast systems, and 28% used insect systems. In 9% and 15% of instances, respectively, plant and mammalian systems were employed.

2.1.3.1 types of VLPs vaccines:

There are many different types of vaccines, including:

- Live-attenuated vaccines
- Inactivated vaccines
- Subunit, recombinant, polysaccharide, or conjugate vaccines
- Toxoid vaccines

2.1.3.2 advantages of VLP vaccination:

The capacity of VLPs to expose antigens repetitively facilitates the cross-linking of B cell receptors (BCRs), an advantageous feature of VLP vaccinations.

VLPs help a person develop robust immunity to a disease because of their repeating surface patterns and particle structure, which elicit powerful immune responses. Additionally, it has been demonstrated that they are extremely safe for the individual receiving the vaccination as well as for those making and delivering it.

This is because the virus-like particle does not contain any functional viral material, making it impossible for the individuals making the vaccine to become infected. This implies that if vaccination-providing personnel come into contact with the particles, they won't get infected.

VLPs are a viable solution to address this problem since viruses are prone to mutation, rendering earlier vaccinations useless in some circumstances. This is so that a VLP's surface proteins may be engineered to combat a particular protein combination on an original viral variant.

In some ways, VLPs are safer than attenuated vaccinations since they cannot multiply.

A VLP vaccine's dangers Generally speaking, VLP vaccinations have the same dangers as other vaccine kinds. The illness that a person is receiving a vaccination against will probably determine any adverse effects that they suffer.

2.1.3.3 Typical adverse reactions to vaccinations include:

Redness, pain, or swelling where the vaccination was administered

- low-grade fever
- Feeling cold
- Weary
- Headaches
- Aches in the muscles
- pains in the joints

These adverse reactions indicate that the body's defenses against the illness being vaccinated against are being bolstered by the immune system.

As with any skin breach, there is a little chance of infection at the injection site if the vaccination is administered.

In general, getting vaccinated against the disease is less dangerous than actually getting the sickness.

3 CONCLUSION:

Technology utilizing recombinant DNA has significantly aided in the creation and manufacture of vaccinations. The following are some of the main uses of rDNA technology in the creation of vaccines:

1. **Subunit vaccinations** are made possible by recombinant DNA technology and include just particular antigens or pieces of pathogens that might trigger an immune response. Scientists can generate significant amounts of pure antigens for use in vaccines by isolating and cloning the genes that encode these antigens. By doing away with the requirement to employ complete pathogens, this method makes subunit vaccinations safer and more targeted.
2. **Vaccines made from recombinant protein:** Recombinant DNA technology enables the creation of vaccines made from recombinant proteins. In host cells, such as bacteria or yeast, genes encoding certain antigens are introduced, causing the host cells to manufacture the desired protein antigens. Without the need for live or attenuated pathogens, these recombinant proteins may be isolated and employed in vaccines to elicit an immune response.
3. **Vaccines made with virus-like particles (VLPs):** VLPs are self-assembling entities that resemble the exterior of viruses but lack the genetic material required for reproduction. VLPs may be created using recombinant DNA technology by expressing the viral structural proteins in host cells. Due to their near resemblance to the real virus, VLPs are good candidates for vaccines against conditions including hepatitis B and the human papillomavirus (HPV).
4. **DNA vaccines:** Plasmid DNA containing genes producing antigenic proteins is directly injected, and they are a sort of genetic vaccination. The desired genes are cloned and inserted into a plasmid vector using recombinant DNA technology before being supplied to host cells. An immune response is triggered by the cells' DNA uptake and production of the antigenic proteins. DNA vaccines have benefits including being simple to produce, stable, and capable of eliciting both cellular and humoral immune responses.
5. **Adjuvants** are chemicals that are added to vaccinations to improve the immune response. New adjuvants that potentially increase the efficacy of vaccinations have been made possible via recombinant DNA technology. Researchers can create adjuvants that strengthen the immune response to antigens and result in greater and longer-lasting immunity by isolating genes encoding immune-stimulating compounds.

These are just a few instances of how recombinant DNA technology has transformed the creation of vaccines. It has given researchers strong tools to create safer and more effective vaccinations against various infectious illnesses.

REFERENCES

1. "Vaccine Types" – United States National Institute of Allergy and Infectious Diseases
2. Nevagi, R. J., Skwarczynski, M., & Toth, I. (2019). Polymers for subunit vaccine delivery. *European Polymer Journal 114*; 397-410. doi:10.1016/j.eurpolymj.2019.03.009.
3. "Vaccine Adjuvants" – United States National Institute of Allergy and Infectious Diseases
4. Vartak, A., & Sucheck, S J. (2016). Recent Advances in Subunit Vaccine Carriers. *Vaccines 4*(2): 12. doi:10.3390/vaccines4020012.
5. "Subunit Vaccines" – World Health Organization
6. "Module 2 - Subunit vaccines". *WHO Vaccine Safety Basics e-learning course*. Archived from the original on 2021-08-08.

7. Jump up to:What are protein subunit vaccines and how could they be used againstCOVID-19?". GAVI. Archived from the original on 2021-08-17.
8. Francis MJ (March 2018). "Recent Advances in Vaccine Technologies". *The Veterinary Clinics of North America. Small Animal Practice*. Vaccines and Immunology. **48** (2): 231–241. doi:10.1016/j.cvsm.2017.10.002. PMC 7132473. PMID 29217317.
9. 16. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Recent advances with recombinant bacterial vaccine vectors. *Mol Med Today.* 2000;6:66–71. [PubMed] [Google Scholar]
10. 17. Curtiss R, III, Xin W, Li Y, Kong W, Wanda SY, Gunn B, et al. New technologies in using recombinant attenuated *Salmonella* vaccine vectors. *Crit Rev Immunol.* 2010;30:255–270. [PMC free article] [PubMed] [Google Scholar]
11. 18. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA. Recombinant *Mycobacterium bovis* BCG. *Vaccine.* 2009;27:6495–6503. [PubMed] [Google Scholar]
12. 8. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. *Dev Biol.* 2005;121:153–163. [PubMed] [Google Scholar]
13. 9. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. *Int J Pharm.* 2008;364:272–280. [PubMed] [Google Scholar]
14. 10. Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and therapeutic potential. *Pathol Biol.* 2010;58:288–295. [PubMed] [Google Scholar]
15. 11. Dertzbaugh MT. Genetically engineered vaccines: an overview. *Plasmid.* 1998;39:100–113. [PubMed] [Google Scholar]
16. 12. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. *BioDrugs.* 1998;10:137–158. [PubMed] [Google Scholar]
17. 1. Plotkin SA. Immunologic correlates of protection induced by vaccination. *Pediatr Infect Dis J.* 2001;20:63–75. [PubMed] [Google Scholar]
18. 2. Ada G. Overview of vaccines and vaccination. *Mol Biotechnol.* 2005;29:255–272. [PMC free article] [PubMed] [Google Scholar]
19. 3. Robinson HL, Amara RR. T cell vaccines for microbial infections. *Nat Med.* 2005;11:S25–S32. [PubMed] [Google Scholar]
20. 4. Lemaire D, Barbosa T, Rihet P. Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology. *Braz J Med Biol Res.* 2012;45:376–385. [PMC free article] [PubMed] [Google Scholar]
21. 5. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. *Immunity.* 2010;33:530–541. [PMC free article] [PubMed] [Google Scholar]
22. 6. Cardoso FC, Pacifico RN, Mortara RA, Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. *Clin Exp Immunol.* 2006;144:382–391. [PMC free article] [PubMed] [Google Scholar]
23. 7. Hansson M, Nygren PA, Stahl S. Design and production of recombinant subunit vaccines. *Biotechnol Appl Biochem.* 2000;32((Part 2)):95–107. [PubMed] [Google Scholar]
24. Akahata, W. *et al*. Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. (2017). https://cvi.asm.org/content/24/7/e00090-17
25. Anderson, D. A., Grgacic, E. V. L. Virus-like particles: passport to immune recognition. (2006). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128828/
26. Bachmann, M. F. *et al*. Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system. (2018). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161069/
27. Cervera, L. *et al*. Production of virus-like particles for vaccines. (2017). https://www.sciencedirect.com/science/article/abs/pii/S1871678416325511
28. Garg, H. *et al*. Virus-like particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese encephalitis, yellow fever, and Zika virus. (2020). https://www.nature.com/articles/s41598-020-61103-1
29. Ilyin, Y. V., Syomin, B. V. Virus-like particles as an instrument of vaccine production. (2019). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088979/
30. Noad, R., Roy, P. Virus-like particles as a vaccine delivery system: myths and facts. (2008). https://www.tandfonline.com/doi/pdf/10.4161/hv.4.1.5559
31. Vaccines. Vaccine side effects. (2020). https://www.vaccines.gov/basics/safety/side_effects
32. Vaccines. Vaccine types. (2020). https://www.vaccines.gov/basics/types
33. Zeltins, A. Construction and characterization of virus-like particles: a review. (2012). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090963/